Editas Medicine Inc
NASDAQ:EDIT
FCF Margin
Free Cash Flow Margin
FCF Margin measures the amount of cash generated by a firm as a proportion of revenue. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
FCF Margin Across Competitors
| Country | Company | Market Cap |
FCF Margin |
||
|---|---|---|---|---|---|
| US |
|
Editas Medicine Inc
NASDAQ:EDIT
|
129.7m USD |
-601%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-15 953%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
323.7B USD |
27%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
146.1B USD |
32%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
133.7B USD |
33%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112B USD |
-11%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-394%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
119.3B AUD |
12%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.7B USD |
21%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-30%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
37.8B USD |
-3%
|
Editas Medicine Inc
Glance View
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.
See Also
FCF Margin measures the amount of cash generated by a firm as a proportion of revenue. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
Based on Editas Medicine Inc's most recent financial statements, the company has FCF Margin of -600.7%.
You don't have any saved screeners yet